News

Press Release

Research, clinical, and company updates from IASO Biotechnology.

Categories

IASO Bio’s CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance

IASO Bio Announces Completion of Enrollment in FUMANBA-3 Phase III Registrational Study of Equecabtagene Autoleucel for Second- and Third-Line Multiple Myeloma

IASO Bio's Registration Application for FUCASO® (equecabtagene autoleucel) Accepted by Australia's TGA

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics

Umoja Biopharma announces United States clinical trial initiation of industry’s first known CD22-targeted In Vivo CAR-T Therapy, developed in collaboration with IASO Bio